The story was updated to include a comment from Life Technologies.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences late Monday announced that a board of the US Patents and Trademark Office has ruled against Life Technologies in a patent interference claim in which PacBio was named the senior party.

As a result of the decision, all patent claims by Life Tech involved in the case were canceled, PacBio said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.